A detailed history of Jim Simons (Renaissance Technologies LLC) transactions in Bio Atla, Inc. stock. As of the latest transaction made, Renaissance Technologies LLC holds 996,300 shares of BCAB stock, worth $1.55 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
996,300
Previous 987,500 0.89%
Holding current value
$1.55 Million
Previous $2.43 Million 41.09%
% of portfolio
0.01%
Previous 0.0%

Shares

10 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 13, 2024

BUY
$1.88 - $3.46 $16,544 - $30,448
8,800 Added 0.89%
996,300 $3.43 Million
Q4 2023

Feb 13, 2024

BUY
$1.27 - $3.18 $460,121 - $1.15 Million
362,300 Added 57.95%
987,500 $2.43 Million
Q3 2023

Nov 14, 2023

SELL
$1.7 - $3.07 $105,862 - $191,175
-62,272 Reduced 9.06%
625,200 $1.06 Million
Q2 2023

Aug 11, 2023

BUY
$2.83 - $3.87 $647,707 - $885,734
228,872 Added 49.91%
687,472 $2.06 Million
Q1 2023

May 12, 2023

SELL
$2.3 - $8.25 $47,839 - $171,600
-20,800 Reduced 4.34%
458,600 $1.23 Million
Q4 2022

Feb 13, 2023

SELL
$7.63 - $11.01 $657,706 - $949,062
-86,200 Reduced 15.24%
479,400 $3.96 Million
Q3 2022

Nov 14, 2022

SELL
$2.94 - $11.87 $631,512 - $2.55 Million
-214,800 Reduced 27.52%
565,600 $4.36 Million
Q2 2022

Aug 12, 2022

BUY
$2.13 - $5.38 $519,573 - $1.31 Million
243,931 Added 45.47%
780,400 $2.22 Million
Q1 2022

May 13, 2022

BUY
$4.38 - $18.78 $2.04 Million - $8.74 Million
465,569 Added 656.66%
536,469 $2.68 Million
Q4 2021

Feb 11, 2022

BUY
$19.0 - $30.95 $1.35 Million - $2.19 Million
70,900 New
70,900 $1.39 Million

Others Institutions Holding BCAB

About BioAtla, Inc.


  • Ticker BCAB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 36,304,100
  • Market Cap $56.6M
  • Description
  • BioAtla, Inc., a clinical stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead product candidate is BA3011, a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for soft tissue and bone sarcoma tumors, non-small cell lung cancer (NSCLC), and ...
More about BCAB
Track Jim Simons's Portfolio

Track Jim Simons Portfolio

Follow Jim Simons (Renaissance Technologies LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Renaissance Technologies LLC, based on Form 13F filings with the SEC.

News

Stay updated on Renaissance Technologies LLC and Jim Simons with notifications on news.